Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Cerus Corporation
  6. Summary
    CERS   US1570851014

CERUS CORPORATION

(CERS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
4.8(c) 4.97(c) 5.04(c) 5.04(c) 5.11(c) Last
1 082 555 905 012 752 024 707 607 802 973 Volume
-0.62% +3.54% +1.41% 0.00% +1.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 111 M - -
Net income 2021 -63,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,7x
Yield 2021 -
Sales 2022 134 M - -
Net income 2022 -58,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -15,1x
Yield 2022 -
Capitalization 875 M 875 M -
Capi. / Sales 2021 7,88x
Capi. / Sales 2022 6,51x
Nbr of Employees 266
Free-Float 97,4%
More Financials
Company
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The... 
More about the company
Ratings of Cerus Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CERUS CORPORATION
07/20CERUS CORPORATION : to Release Second Quarter 2021 Financial Results on August 3..
BU
07/14CERUS CORPORATION : and the Swiss Red Cross Celebrate 10 Years of Routine Use of..
BU
06/30CERUS : Announces Collaboration with LifeSouth Community Blood Centers to Manufa..
BU
06/30Cerus Announces Collaboration with LifeSouth Community Blood Centers to Manuf..
CI
06/14CERUS CORPORATION : Celebrates World Blood Donor Day 2021
BU
06/07CERUS CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/17CERUS CORPORATION : Announces Contract with Canadian Blood Services for INTERCEP..
BU
05/17Cerus Corporation Announces Contract with Canadian Blood Services for INTERCE..
CI
05/04CERUS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/04CERUS : Q1 Earnings Snapshot
AQ
05/04CERUS : Q1 Net Loss Meets Street View, Revenue Gain a Surprise
MT
05/04CERUS CORP : Results of Operations and Financial Condition, Financial Statements..
AQ
05/04CERUS : Earnings Flash (CERS) CERUS CORPORATION Reports Q1 Revenue $29.6M, vs. S..
MT
05/04CERUS CORPORATION : Announces First Quarter 2021 Financial Results and Raises Fu..
BU
05/04Cerus Corporation Reports Earnings Results for the First Quarter Ended March ..
CI
More news
News in other languages on CERUS CORPORATION
2007CERUS CORP : Cerus annonce avoir passé un accord portant sur la fourniture du sy..
2007CERUS CORP : INTERCEPT Plasma inscrit au Journal Officiel français
2006CERUS CORP : Cerus Corporation annonce avoir reçu l?homologation réglementaire e..
2006CERUS CORP : Cerus renforce son équipe de gestion européenne
More news
Chart CERUS CORPORATION
Duration : Period :
Cerus Corporation Technical Analysis Chart | CERS | US1570851014 | MarketScreener
Technical analysis trends CERUS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 5,11 $
Average target price 8,75 $
Spread / Average Target 71,2%
EPS Revisions
Managers and Directors
William Mariner Greenman President, Chief Executive Officer & Director
Kevin Dennis Green Chief Financial Officer & Vice President-Finance
Daniel N. Swisher Chairman
Laurence M. Corash Chief Scientific Officer
Carol M. Moore Senior VP-Regulatory Affairs, Quality & Clinical
Sector and Competitors